Multinational Pharma Giants Step Up Strategic Moves Amid Market Shifts

　　【Pharmaceutical Network Industry Dynamics】In recent times, many multinational pharmaceutical companies, including Takeda Pharmaceutical, Johnson & Johnson, and Fuji Irvine Bio, have been making frequent moves, mainly involving merging product lines, building new business experience centers, and innovation cooperation centers.
 

　　Takeda Pharmaceuticals: Consolidated Product Lines
 

Recently, Takeda Pharmaceutical China confirmed that the product lines of Pantoprazole Sodium Enteric-Coated Tablets and Vonoprazan Fumarate Tablets will be merged to better respond to the market environment.
 

Among them, Vonoprazan Fumarate Tablets are a new drug in the market for oral preparations treating peptic ulcers and also the first Potassium-Competitive Acid Blocker (P-CAB) to be launched in China. Its indication is for reflux esophagitis. This product was approved for marketing by the National Medical Products Administration at the end of 2019 and officially launched in China in May 2020. Currently, it has been included in the 2020 National Reimbursement Drug List. Data shows that in the first half of 2021, the sales revenue of Vonoprazan Fumarate Tablets in public medical institutions in China exceeded 30 million yuan, showing great growth potential. It is currently facing competition from generic drug manufacturers such as Shandong New Era and Sichuan Haihui.
 

Pantoprazole Sodium Enteric-Coated Tablets are suitable for the treatment of duodenal ulcers, gastric ulcers, and moderate to severe reflux esophagitis. This product is classified under National Medical Insurance Category B. Currently, China has approved Pantoprazole Sodium.Active Pharmaceutical Ingredients, enteric-coated tablets, enteric-coated capsules, injections, and other formulations have been launched. Among them, Pantoprazole Sodium Enteric-Coated Tablets (40mg) and Injectable Pantoprazole Sodium (40mg) have successfully entered the fourth round of national procurement in China. Relevant data shows that the sales revenue of Pantoprazole Sodium Enteric-Coated Tablets in 2020 within China amounted to approximately 3.33 billion yuan.
 

Industry insiders say that digestion is Takeda's traditional area of strength, with a complete R&D pipeline including core disease areas such as inflammatory bowel disease, celiac disease, and other intestinal disorders, as well as gastrointestinal motility disorders. This adjustment may represent Takeda China's repositioning in the significant digestive field.
 

　　Johnson & Johnson: Vision Experience Center Launches in China
 

Recently, Johnson & Johnson Vision Experience Center has been officially completed. This center is one of the important education and training bases in the professional ophthalmology field for Johnson & Johnson Vision, the eye health business unit under Johnson & Johnson.
 

With the aggravation of aging, as well as changes in people's living habits and eye-use patterns, the number of patients suffering from various ophthalmic diseases such as refractive errors, cataracts, and dry eye is increasing. Statistics show that, without considering overlapping cases, the number of patients with only myopia, dry eye syndrome, and cataracts has already exceeded 1 billion. However, the construction of professional ophthalmology teams in China is facing severe challenges.
 

It is reported that the Johnson & Johnson Vision Experience Center has three main areas: a microscopic phacoemulsification training area, an astigmatism marking training area, and a dry eye diagnosis and treatment area. Equipped with professional ophthalmic devices and many advanced training facilities, it will provide 300 to 400 middle-aged and young ophthalmologists each year with professional training scenarios and courses, including animal eye experiments, optical parameter measurements, and dry eye diagnosis and treatment, thereby enhancing the cataract surgery skills of grassroots doctors.
 

　　Fujifilm Irvine Scientific: ICC Innovation Cooperation Center Opens
 

Recently, "Fujifilm Irvine Scientific (Suzhou) Co., Ltd.", a subsidiary of Fujifilm, announced the official opening of its ICC Innovation Collaboration Center located in Suzhou New District.
 

According to the introduction, the center will provide a variety of culture medium development and optimization services to customers in the entire Greater China region in the future, to meet the growing market demand in China.
 

Data shows that Fujifilm Irvine Biologics is committed to providing high-quality cell culture media and customized culture media solutions to customers worldwide, supporting their large-scale commercial production.